
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
An otherwise healthy 15-year-old boy tells you that he has had six days of documented fever, a slight cough, and back pain that shifts location.






